Gilead Sciences Inc articles over last 30 days

- articles last 30 days - articles per day
Mentioned in this news Places Companies People
2015/03/04 22:45
2015/03/04 22:45
10h
The money pileup, reflecting companies’ incentives to park profits in low-tax countries, has drawn the attention of President Barack Obama and U.S. lawmakers, who see a chance to tap the funds for...
2015/03/04 22:45
2015/03/04 22:45
Latest videos
2015/03/03 17:19
2015/03/03 17:19
1d
PASADENA, Calif.--(BUSINESS WIRE)--CohBar, Inc. (TSX-V: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics to treat diseases associated with aging, today...
2015/03/03 06:27
2015/03/03 06:27
2d
... is a daily report on global news about patents, trademarks, copyright and other intellectual property topics. To be sent this column daily, click SALT IPREPORT .) (Bloomberg) -- Natco...
2015/03/02 22:17
2015/03/02 22:17
2d
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Cowen and Company 35th Annual Health Care Conference...
2015/03/02 15:44
2015/03/02 15:44
2d
... Gilead Sciences Inc., whose $1,000-a-pill hepatitis C treatment is one of the world�s most expensive drugs, is avoiding billions of dollars in U.S. taxes by booking profits overseas. The...
2015/03/02 11:43
2015/03/02 11:43
2d
Natco Pharma Limited said on Monday it signed a licensing deal with Gilead Sciences Inc to make and sell generic versions of the US drugmaker's chronic hepatitis C medicines. Drugs under the deal...
2015/03/02 11:39
2015/03/02 11:39
2d
In less than two decades exchange-traded funds have grown from a few ETFs that tracked major global indices to countless numbers that touch on almost every imaginable avenue of investing. Their...
2015/02/28 14:17
2015/02/28 14:17
4d
SEATTLE--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) ha comunicato in data odierna i risultati dettagliati a 48 settimane derivati da due studi di Fase 3 (Studi 104 e Studio 111) inteso a...
2015/02/28 14:17
2015/02/28 14:17
4d
SEATTLE--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) maakte vandaag de resultaten na 48 weken bekend van twee fase 3-studies (studies 104 en 111) ter beoordeling van het onderzoeksregime van...
2015/02/28 07:17
2015/02/28 07:17
5d
SEATTLE--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ : GILD) a annoncé aujourd’hui les résultats détaillés à 48 semaines de deux études de phase 3 (études 104 et 111) évaluant son schéma...
2015/02/27 18:17
2015/02/27 18:17
5d
SEATTLE, Washington State (USA)--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) hat heute Ergebnisse aus einer Phase-3-Studie (ION-4) bekannt gegeben, bei der das einmal täglich in einer...
2015/02/27 15:17
2015/02/27 15:17
5d
SEATTLE--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) ha anunciado los resultados de un estudio de Fase 3, ION-4, que evalúa el régimen de único comprimido diario de Harvoni® (ledipasvir 90...
2015/02/27 00:17
2015/02/27 00:17
6d
SEATTLE--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48-week results from two Phase 3 studies (Studies 104 and 111) evaluating its investigational once-daily single...
2015/02/26 20:17
2015/02/26 20:17
6d
SEATTLE--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today announced results from a Phase 3 study, ION-4, evaluating the once-daily single tablet regimen Harvoni® (ledipasvir 90 mg/sofosbuvir...
2015/02/25 13:39
2015/02/25 13:39
7d
These are stories Report on Business is following Wednesday, Feb. 25, 2015. Targets takes big hit Target Corp. is having its “Blame Canada” moment today, posting a $2.6-billion quarterly loss on its...
2015/02/24 22:17
2015/02/24 22:17
8d
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the RBC Capital Markets 2015 Healthcare Conference in...
2015/02/24 18:09
2015/02/24 18:09
8d
Bristol-Myers Squibb Co. has announced two deals valued at a total of about $1.6 billion that will further strengthen the drug maker's oncology pipeline. The deals with Flexus Biosciences Inc. and...
2015/02/23 22:09
2015/02/23 22:09
9d
Earnings excluding certain items were at the higher end of expectations and revenue beat Wall Street estimates. However, for the first quarter, the St. Louis-based company forecast per-share earnings...
2015/02/19 12:27
2015/02/19 12:27
13d
Paying for gene therapy: are annuities the next big thing? LOS ANGELES (Reuters) - As U.S. drugmakers face growing resistance to the high price of cutting-edge treatments, a handful of companies are...
2015/02/18 16:56
2015/02/18 16:56
14d
Sales per share is overlooked in most earnings press releases and in the business media, but it is a very useful measure of a company’s success. Earnings headlines typically tell us whether a company...
2015/03/04 22:45
2015/03/04 22:45
Latest from Twitter